Pancreatic cancer: a review of recent advances

Bibliography

• JEMAL A, TIWARI RC, MURRAY T et al.: Cancer statistics, 2004. CA Cancer J. Clin. (2004) 54(1):8-29.
   PubMed Web of Science ®Google Scholar
• SENER SF, FREMGEN A, MENCK HR, WINCHESTER DP: Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J. Am. Coll. Surg. (1999) 189(1):1-7.
   PubMed Web of Science ®Google Scholar
• RICHTER A, NIEDERGETHMANN M, STURM JW et al.: Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J. Surg. (2003) 27(3):324-329.
   PubMed Web of Science ®Google Scholar
• NEOPTOLEMOS JP, STOCKEN DD, FRIESS H et al.: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N. Engl. J. Med. (2004) 350(12):1200-1210.
   PubMed Web of Science ®Google Scholar
• NEUHAUS P, OETTLE H, POST S et al.: A randomised, prospective, multicenter, Phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer. Proc. Am. Soc. Clin. Oncol. (2005) 23(16S):1092s (Abstract LBA4013).
   Google Scholar
• SCHNEIDER G, SIVEKE JT, ECKEL F, SCHMID RM: Pancreatic cancer: basic and clinical aspects. Gastroenterology (2005) 128(6):1606-1625.
   PubMed Web of Science ®Google Scholar
• HEZEL AF, KIMMELMAN AC, STANGER BZ, BARDEESY N, DEPINHO RA: Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. (2006) 20(10):1218-1249.
   PubMed Web of Science ®Google Scholar
• HRUBAN RH, ADSAY NV, ALBORES-SAAVEDRA J et al.: Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am. J. Surg. Pathol. (2001) 25(5):579-586.
   PubMed Web of Science ®Google Scholar
• SCHMITT CA: Senescence, apoptosis and therapy-cutting the lifelines of cancer. Nat. Rev. Cancer (2003) 3(4):286-295.
   Google Scholar
• LOWE SW, CEPERO E, EVAN G: Intrinsic tumour suppression. Nature (2004) 432(7015):307-315.
   PubMed Web of Science ®Google Scholar
• SCHULZE-BERGKAMEN H, KRAMMER PH: Apoptosis in cancer-implications for therapy. Semin. Oncol. (2004) 31(1):90-119.
   PubMed Web of Science ®Google Scholar
• BURRIS HA III, MOORE MJ, ANDERSEN J et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. (1997) 15(6):2403-2413.
   PubMed Web of Science ®Google Scholar
• ROTHENBERG ML, MOORE MJ, CRIPPS MC et al.: A Phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann. Oncol. (1996) 7(4):347-353.
   PubMed Web of Science ®Google Scholar
• BRAMHALL SR, ROSEMURGY A, BROWN PD, BOWRY C, BUCKELS JA: Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J. Clin. Oncol. (2001) 19(15):3447-3455.
   PubMed Web of Science ®Google Scholar
• BRAMHALL SR, SCHULZ J, NEMUNAITIS J et al.: A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br. J. Cancer (2002) 87(2):161-167.
   PubMed Web of Science ®Google Scholar
• MOORE MJ, HAMM J, DANCEY J et al.: Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a Phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. (2003) 21(17):3296-3302.
   PubMed Web of Science ®Google Scholar
• CHEVERTON P, FRIESS H, ANDRAS C et al.: Phase III results of exatecan (DX-8951f) versus gemcitabine (Gem) in chemotherapy-naïve patients with advanced pancreatic cancer (APC). Proc. Am. Soc. Clin. Oncol. (2004) 22:4005.
   Google Scholar
• BERLIN JD, CATALANO P, THOMAS JP et al.: Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J. Clin. Oncol. (2002) 20(15):3270-3275.
   PubMed Web of Science ®Google Scholar
• HEINEMANN V, QUIETZSCH D, GIESELER F et al.: A Phase III trial comparing gemcitabine plus cisplatin versus gemcitabine alone in advanced pancreatic carcinoma. Proc. Am. Soc. Clin. Oncol. (2003) 21:1003 (Abstract).
   Web of Science ®Google Scholar
• COLUCCI G, GIULIANI F, GEBBIA V et al.: Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized Phase III study of the Gruppo Oncologia dell’Italia Meridionale. Cancer (2002) 94(4):902-910.
   PubMed Web of Science ®Google Scholar
• O’REILLY EM, ABOU-ALFA GK, LETOURNEAU R et al.: A randomized Phase III trial of DX-8951f (exatecan mesylate; DX) and gemcitabine (GEM) versus gemcitabine alone in advanced pancreatic cancer (APC). Proc. Am. Soc. Clin. Oncol. (2004) 22:4006.
   Google Scholar
• ROCHA LIMA CM, GREEN MR, ROTCHE R et al.: Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J. Clin. Oncol. (2004) 22(18):3776-3783.
   PubMed Web of Science ®Google Scholar
• VAN CUTSEM E, VAN DE VELDE H, KARASEK P et al.: Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J. Clin. Oncol. (2004) 22(8):1430-1438.
   PubMed Web of Science ®Google Scholar
• LOUVET C, LABIANCA R, HAMMEL P et al.: Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD Phase III trial. J. Clin. Oncol. (2005) 23(15):3509-3516.
   PubMed Web of Science ®Google Scholar
• RENI M, CORDIO S, MILANDRI C et al.: Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre Phase III trial. Lancet Oncol. (2005) 6(6):369-376.
   PubMed Web of Science ®Google Scholar
• RIESS H, HELM A, NIEDERGETHMANN M et al.: A randomised, prospective, multicenter, Phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid versus gemcitabine alone in patients with advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol. (2005).
   Google Scholar
• HERRMANN R, BODOKY G, RUHSTALLER T et al.: Gemcitabine (G) plus capecitabine (C) versus G alone in locally advanced or metastatic pancreatic cancer. A randomized Phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG). Proc. Am. Soc. Clin. Oncol. (2005).
   Google Scholar
• CUNNINGHAM D, CHAU I, STOCKEN D et al.: Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM–CAP) in patients with advanced pancreatic cancer. Eur. J. Cancer Suppl. (2005) 3(4):4.
   Google Scholar
• MOORE MJ, GOLDSTEIN D, HAMM J et al.: Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A Phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. Proc. Am. Soc. Clin. Oncol. (2005):1 (Abstract).
   PubMed Web of Science ®Google Scholar
• OETTLE H, RICHARDS D, RAMANATHAN RK et al.: A Phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann. Oncol. (2005) 16(10):1639-1645.
   PubMed Web of Science ®Google Scholar
• TEMPERO M, PLUNKETT W, RUIZ VAN HAPEREN V et al.: Randomized Phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J. Clin. Oncol. (2003) 21(18):3402-3408.
   PubMed Web of Science ®Google Scholar
• POPLIN E, LEVY DE, BERLIN J et al.: Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion [FDR]) versus gemcitabine + oxaliplatin (GEMOX) in patients with advanced pancreatic cancer (E6201). Proc. Am. Soc. Clin. Oncol. (2006) 24(18S):LBA4004 (Abstract).
   Google Scholar
• VAN MOORSEL CJ, PINEDO HM, VEERMAN G et al.: Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br. J. Cancer (1999) 80(7):981-990.
   PubMed Web of Science ®Google Scholar
• MOUFARIJ MA, PHILLIPS DR, CULLINANE C: Gemcitabine potentiates cisplatin cytotoxicity and inhibits repair of cisplatin-DNA damage in ovarian cancer cell lines. Mol. Pharmacol. (2003) 63(4):862-869.
   PubMed Web of Science ®Google Scholar
• LOUVET C, HINCKE A, LABIANCA R, HEINEMANN V: Increased survival using platinum analog combined with gemcitabine as compared to gemcitabine single agent in advanced pancreatic cancer (APC): pooled analysis of two randomised trials, the GERCOR/GISCAD Intergroup Study and a German Multicenter Study. Proc. Am. Soc. Clin. Oncol. (2006) 24(18S):4003 (Abstract).
   PubMed Web of Science ®Google Scholar
• STATHOPOULOS GP, SYRIGOS K, POLYZOS A et al.: Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, Phase II study. Ann. Oncol. (2004) 15(2):224-229.
   PubMed Web of Science ®Google Scholar
• CONROY T, PAILLOT B, FRANCOIS E et al.: Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer-a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. J. Clin. Oncol. (2005) 23(6):1228-1236.
   PubMed Web of Science ®Google Scholar
• CANTORE M, RABBI C, FIORENTINI G et al.: Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer. Oncology (2004) 67(2):93-97.
   PubMed Web of Science ®Google Scholar
• KOZUCH P, GROSSBARD ML, BARZDINS A et al.: Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer. Oncologist (2001) 6(6):488-495.
   PubMed Web of Science ®Google Scholar
• RACHAMALLA R, MALAMUD S, GROSSBARD ML et al.: Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors. Anti-Cancer Drugs (2004) 15(3):211-217.
   Google Scholar
• LUTZ MP, CUTSEM EV, WAGENER T et al.: Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized Phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group. J. Clin. Oncol. (2005) 23(36):9250-9256.
   PubMed Web of Science ®Google Scholar
• KURTZ JE, NEGRIER S, HUSSEINI F et al.: A Phase II study of docetaxel–irinotecan combination in advanced pancreatic cancer. Hepatogastroenterology (2003) 50(50):567-570.
   PubMed Web of Science ®Google Scholar
• JACOBS AD, BURRIS HA, RIVKIN S et al.: A randomized Phase III study of rubitecan (ORA) versus best choice (BC) in 409 patients with refractory pancreatic cancer report from a North-American multi-center study. Proc. Am. Soc. Clin. Oncol. (2004):4013 (Abstract).
   Web of Science ®Google Scholar
• PAPISH SW, RAMANATHAN R, PINCUS J, HIRMAND M, BURRIS HA: Patients rescued by crossover to rubitecan in Phase III study of rubitecan capsules versus 5-FU in pancreatic cancer. Proc. Am. Soc. Clin. Oncol. (2005) 23:4165 (Abstract).
   Google Scholar
• BRIASOULIS E, PAVLIDIS N, TERRET C et al.: Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A Phase II trial of the EORTC-new drug development group. Eur. J. Cancer (2003) 39(16):2334-2340.
   PubMed Web of Science ®Google Scholar
• LAPOINTE R, LETOURNEAU R, STEWARD W et al.: Phase II study of troxacitabine in chemotherapy-naive patients with advanced cancer of the pancreas: gastrointestinal tumors. Ann. Oncol. (2005) 16(2):289-293.
   PubMed Web of Science ®Google Scholar
• NAKAMURA K, YAMAGUCHI T, ISHIHARA T et al.: Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br. J. Cancer (2005) 92(12):2134-2139.
   PubMed Web of Science ®Google Scholar
• UENO H, OKUSAKA T, IKEDA M et al.: A Phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer. Oncology (2005) 69(5):421-427.
   PubMed Web of Science ®Google Scholar
• ULRICH-PUR H, RADERER M, VERENA KORNEK G et al.: Irinotecan plus raltitrexed versus raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. Br. J. Cancer (2003) 88(8):1180-1184.
   PubMed Web of Science ®Google Scholar
• VAN LAETHEM JL, VAN MAELE P, VERSLYPE C et al.: Raltitrexed plus gemcitabine (TOMGEM) in advanced pancreatic cancer. Results of a Belgian multicentre Phase II study. Oncology (2004) 67(5-6):338-343.
   PubMed Web of Science ®Google Scholar
• ARENDS JJ, SLEEBOOM HP, LEYS MB et al.: A Phase II study of raltitrexed and gemcitabine in patients with advanced pancreatic carcinoma. Br. J. Cancer (2005) 92(3):445-448.
   PubMed Web of Science ®Google Scholar
• FRANCOIS E, HEBBAR M, BENNOUNA J et al.: A Phase II trial of raltitrexed (Tomudex) in advanced pancreatic and biliary carcinoma. Oncology (2005) 68(4-6):299-305.
   PubMed Web of Science ®Google Scholar
• KINDLER HL, FRIBERG G, SINGH DA et al.: Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J. Clin. Oncol. (2005) 23(31):8033-8040.
   PubMed Web of Science ®Google Scholar
• DONG M, NIO Y, GUO KJ et al.: Epidermal growth factor and its receptor as prognostic indicators in Chinese patients with pancreatic cancer. Anti-Cancer Res. (1998) 18(6B):4613-4619.
   PubMed Web of Science ®Google Scholar
• JOHNSON BE, JANNE PA: Epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Cancer Res. (2005) 65(17):7525-7529.
   PubMed Web of Science ®Google Scholar
• PAEZ JG, JANNE PA, LEE JC et al.: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 304(5676):1497-1500.
   PubMed Web of Science ®Google Scholar
• CUNNINGHAM D, HUMBLET Y, SIENA S et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. (2004) 351(4):337-345.
   PubMed Web of Science ®Google Scholar
• XIONG HQ, ROSENBERG A, LOBUGLIO A et al.: Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter Phase II Trial. J. Clin. Oncol. (2004) 22(13):2610-2616.
   PubMed Web of Science ®Google Scholar
• SHADAD F, MATIN K, EVANS TL et al.: Phase II study of gefitinib and docetaxel as salvage therapy in patients (pts) with advanced pancreatic adenocarcinoma (APC). J. Clin. Oncol., 2006 ASCO Annual Meeting Proceedings (Post-meeting edition) (2006) 24(Supplement 18S):4120.
   Google Scholar
• CZITO BG, WILLETT CG, BENDELL JC et al.: Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: Phase I trial results. J. Clin. Oncol. (2006) 24(4):656-662.
   PubMed Web of Science ®Google Scholar
• YINGLING JM, BLANCHARD KL, SAWYER JS: Development of TGF-β signalling inhibitors for cancer therapy. Nat. Rev. Drug Discov. (2004) 3(12):1011-1022.
   Google Scholar
• STAUDER G, BISCHOF A, EGGER T et al.: TGF-β2 suppression by the antisense oligonucleotide AP 12009 as treatment for pancreatic cancer: preclinical efficacy data. Proc. Am. Soc. Clin. Oncol. (2004):4106 (Abstract).
   Google Scholar
• YINGLING JM, BLANCHARD KL, SAWYER JS: Development of TGF-β signalling inhibitors for cancer therapy. Nat. Rev. (2004) 3:1011-1022.
   Google Scholar
• HAU P, STOCKHAMMER G, KUNST M et al.: Results of G004, a Phase IIb actively controlled clinical trial with the TGF-β2 targeted compound AP 12009 for recurrent anaplastic astrocytoma. Proc. Am. Soc. Clin. Oncol. (2006) 24(18S):1566 (Abstract).
   Google Scholar
• BOGDAHN U, OLIUSHINE VE, PARFENOV VE et al.: Results of G004, a Phase IIb study in recurrent glioblastoma patients with the TGF-b2 targeted compound AP 12009. Proc. Am. Soc. Clin. Oncol. (2006) 24(18S):1553 (Abstract).
   Google Scholar
• SIU LL, AWADA A, TAKIMOTO CH et al.: Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin. Cancer Res. (2006) 12(1):144-151.
   PubMed Web of Science ®Google Scholar
• RINEHART J, ADJEI AA, LORUSSO PM et al.: Multicenter Phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J. Clin. Oncol. (2004) 22(22):4456-4462.
   PubMed Web of Science ®Google Scholar
• ALBERTS SR, FOSTER NR, MORTON RF et al.: PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized Phase II study. Ann. Oncol. (2005) 16(10):1654-1661.
   PubMed Web of Science ®Google Scholar
• ALBERTS SR, SCHROEDER M, ERLICHMAN C et al.: Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group Phase II trial. J. Clin. Oncol. (2004) 22(24):4944-4950.
   PubMed Web of Science ®Google Scholar
• MACDONALD JS, McCOY S, WHITEHEAD RP et al.: A Phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study. Invest. New Drugs (2005) 23(5):485-487.
   PubMed Web of Science ®Google Scholar
• COHEN SJ, HO L, RANGANATHAN S et al.: Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J. Clin. Oncol. (2003) 21(7):1301-1306.
   PubMed Web of Science ®Google Scholar
• MARTIN NE, BRUNNER TB, KIEL KD et al.: A Phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer. Clin. Cancer Res. (2004) 10(16):5447-5454.
   PubMed Web of Science ®Google Scholar
• SZLOSAREK P, CHARLES KA, BALKWILL FR: Tumour necrosis factor-α as a tumour promoter. Eur. J. Cancer (2006) 42(6):745-750.
   PubMed Web of Science ®Google Scholar
• YOKOI K, SASAKI T, BUCANA CD et al.: Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model. Cancer Res. (2005) 65(22):10371-10380.
   PubMed Web of Science ®Google Scholar
• BERGERS G, SONG S, MEYER-MORSE N, BERGSLAND E, HANAHAN D: Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. (2003) 111(9):1287-1295.
   PubMed Web of Science ®Google Scholar
• HECHT JR, TRARBACH T, JAEGER E et al.: A randomized, double-blind, placebo-controlled, Phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). Proc. Am. Soc. Clin. Oncol. (2005):3 (Abstract).
   Web of Science ®Google Scholar
• FERRARI V, VALCAMONICO F, AMOROSO V et al.: Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a Phase II trial. Cancer Chemother. Pharmacol. (2006) 57(2):185-190.
   PubMed Web of Science ®Google Scholar
• ZAGON IS, JAGLOWSKI JR, VERDERAME MF et al.: Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma. Cancer Chemother. Pharmacol. (2005) 56(5):510-520.
   PubMed Web of Science ®Google Scholar
• SMITH JP, CONTER RL, BINGAMAN SI et al.: Treatment of advanced pancreatic cancer with opioid growth factor: Phase I. Anti-Cancer Drugs (2004) 15(3):203-209.
   Google Scholar
• ECKEL F, LERSCH C, LIPPL F et al.: Monitoring of tumour glucose metabolism by PET in a Phase I study evaluating hormonal therapy in advanced pancreatic cancer. Scand. J. Gastroenterol. (2002) 37(8):972-977.
   Google Scholar
• WRIGHT JA, OSTERLEE J, FEKETE S, LEE Y, YOUNG AH: A Phase III trial of virulizin plus gemcitabine versus gemcitabine alone in advanced pancreatic cancer: results of subgroup analysis. Proc. Am. Soc. Clin. Oncol. (2006) 24(18S):4116 (Abstract).
   PubMed Web of Science ®Google Scholar
• SMITH JP, FANTASKEY AP, LIU G, ZAGON IS: Identification of gastrin as a growth peptide in human pancreatic cancer. Am. J. Physiol. (1995) 268(1 Part 2):R135-R141.
   PubMed Web of Science ®Google Scholar
• BRETT BT, SMITH SC, BOUVIER CV et al.: Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer. J. Clin. Oncol. (2002) 20(20):4225-4231.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO K, UENO T, KAWAOKA T et al.: MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer. Anti-Cancer Res. (2005) 25(5):3575-3579.
   PubMed Web of Science ®Google Scholar
• RAMANATHAN RK, LEE KM, McKOLANIS J et al.: Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol. Immunother. (2005) 54(3):254-264.
   PubMed Web of Science ®Google Scholar
• BUANES T, MEO MA, GJERTSEN MK et al.: Vaccination with a telomerase peptide induces immune responses in patients with advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol. (2002) 21:1891 (Abstract).
   Google Scholar
• GJERTSEN MK, BUANES T, ROSSELAND AR et al.: Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: clinical and immunological responses in patients with pancreatic adenocarcinoma. Int. J. Cancer (2001) 92(3):441-450.
   PubMed Web of Science ®Google Scholar
• JAFFEE EM, HRUBAN RH, BIEDRZYCKI B et al.: Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a Phase I trial of safety and immune activation. J. Clin. Oncol. (2001) 19(1):145-156.
   PubMed Web of Science ®Google Scholar
• SANGRO B, MAZZOLINI G, RUIZ J et al.: Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J. Clin. Oncol. (2004) 22(8):1389-1397.
   PubMed Web of Science ®Google Scholar
• GORDON EM, CORNELIO GH, LORENZO CC III et al.: First clinical experience using a ‘pathotropic’ injectable retroviral vector (Rexin-G) as intervention for stage IV pancreatic cancer. Int. J. Oncol. (2004) 24(1):177-185.
   Web of Science ®Google Scholar
• HECHT JR, BEDFORD R, ABBRUZZESE JL et al.: A Phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin. Cancer Res. (2003) 9(2):555-561.
   PubMed Web of Science ®Google Scholar
• LOHR M, HOFFMEYER A, KROGER J et al.: Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma. Lancet (2001) 357(9268):1591-1592.
   PubMed Web of Science ®Google Scholar